Medtronic closed two cardiovascular deals in 48 hours and didn’t blink. First came the completion of the $585 million CathWorks acquisition on April 20 — folding an AI-powered coronary physiology platform into Medtronic’s cath lab portfolio after three years of co-promotion. Then, on April 19, Medtronic led a $100 million round into Pulnovo Medical, signing a commercial agreement for pulmonary artery denervation technology in the same breath. Two different disease areas. One unmistakable thesis: the wire-guided cath lab has a replacement coming. Meanwhile, AcuityMD raised $80 million at a $955 million valuation to bring agentic AI to MedTech commercial teams. The data layer and the device layer are both getting smarter at once. Welcome to Issue #16 of The MedTech Minute.
Top Stories
Story 01
The wires came out. On April 20, Medtronic announced the closing of its $585 million acquisition of CathWorks, the Israeli medical device company whose FFRangio System uses artificial intelligence and computational science to derive fractional flow reserve (FFR) measurements across the entire coronary tree from routine angiograms — no pressure wires, no pharmacologic hyperemia required.
CathWorks had been commercially available in the U.S., Europe, and Japan since receiving FDA clearance in 2018, and Medtronic had co-promoted the system since a 2022 strategic partnership. The acquisition closes a chapter that began with a $75 million minority investment and three years of joint commercial execution. Under Medtronic’s global distribution infrastructure, FFRangio now has a runway that CathWorks could not have built as a standalone company. (Source: Repertoire Magazine, April 20, 2026)
Why It Matters: Traditional wire-based FFR captures one measurement at one point in the vessel. FFRangio captures the entire coronary tree in a single pass from images that were already being acquired. When the diagnostic tool is faster, non-invasive, and provides more data, the standard of care shifts — not through regulatory mandate but through clinical preference. Medtronic now owns the technology most likely to displace the wire-based segment it also competes in.
Acquisition Closed
AI-Guided
Coronary Physiology
Why This Matters for Builders
The “try-before-you-buy” structure of this deal is a case study in de-risked acquisition strategy. Medtronic invested $75 million in 2022, locked in a co-promotion option, ran three years of real commercial data, then exercised. By the time they paid $585 million, they already knew adoption rates, physician feedback, and competitive dynamics. For MedTech founders: strategic partnerships with large OEMs are not just commercial agreements — they are priced call options. Structure them like it.
Story 02
Twenty-four hours before the CathWorks close, Medtronic announced it had led a $100 million strategic financing round into Pulnovo Medical, a Chinese medical device company focused on pulmonary hypertension (PH) and heart failure. The oversubscribed round closed April 19 and included EQT, Qiming Venture Partners, OrbiMed, Lilly Asia Ventures, and new investor HSG (formerly Sequoia China).
Pulnovo’s core technology is pulmonary artery denervation (PADN) — a radiofrequency ablation procedure targeting the pulmonary sympathetic nerve network to reduce pulmonary artery pressure and slow disease progression. The PADN catheter holds FDA Breakthrough Device designation for Groups I, II, and IV pulmonary hypertension and received CE Mark clearance under EU MDR in April 2025. It is the only commercially available interventional PH therapy globally, already cleared in China. Separately from the investment, Medtronic and Pulnovo signed a commercial agreement covering potential future co-commercialization of PADN. The funding will support FDA trials for Group I and Group II PH planned for 2026. (Source: PR Newswire, April 19, 2026)
Why It Matters: Medtronic already runs the largest renal denervation franchise in MedTech following FDA approval of its Symplicity Spyral system. Adding a commercial agreement with Pulnovo positions Medtronic to extend the denervation playbook into pulmonary hypertension — a market where current medical therapy is expensive, chronic, and leaves a large unmet need for durable interventional options. Two denervation bets in one portfolio: one for hypertension, one for PH.
$100M Investment
Pulmonary Hypertension
Breakthrough Device
Story 03
On April 21, AcuityMD announced $80 million in Series C funding led by StepStone Group, with participation from Benchmark, Redpoint Ventures, ICONIQ, and Atreides Management. The round values the Boston-based company at $955 million — one data round away from unicorn status — and brings total capital raised to more than $160 million.
AcuityMD operates a commercial intelligence platform used by 16 of the top 20 MedTech companies and over 400 device manufacturers. Its proprietary MedTech ontology aggregates claims databases, FDA filings, government records, and market signals to map physicians, facilities, procedures, reimbursement dynamics, and the relationships between them. The new funding powers three initiatives: launching AcuityAI (an agentic AI layer now in open beta that delivers real-time contextual intelligence to sales reps and commercial leaders), deepening the data ontology, and expanding the platform beyond commercial sales to cover the full product lifecycle. The company has helped customers identify over $34 billion in pipeline opportunity to date. (Source: HIT Consultant, April 21, 2026)
Why It Matters: MedTech commercialization has been data-poor relative to other industries — reps operating on tribal knowledge, sales leaders relying on manual territory models, launches under-indexed to real-world procedure volumes. AcuityMD’s ontology closes that gap. When agentic AI runs on top of a clean, proprietary data model of the entire MedTech commercial ecosystem, the competitive advantage compounds. The company is building what becomes infrastructure-grade software for device commercialization.
$80M Series C
Agentic AI
$955M Valuation
Industry Shift
Story 04
GE HealthCare announced the completion of its acquisition of Intelerad on April 22, accelerating the company’s shift toward a cloud-first enterprise platform for precision care. Intelerad provides medical imaging and workflow solutions deployed across hospital systems, radiology groups, and imaging networks — a software layer that sits above scanner hardware and connects acquisition, interpretation, and clinical decision-making.
The deal extends the imaging oligopoly consolidation theme that has been building since GE separated from General Electric in January 2023. As GE HealthCare, Philips, and Siemens Healthineers each pursue full independence and expand their software portfolios, the competitive dynamic in medical imaging is shifting from hardware differentiation toward who controls the clinical workflow above the scanner. GE’s acquisition of Intelerad adds enterprise imaging software to the portfolio it already built with the RadNet AI mammography partnership and the Pristina Via platform.
Why It Matters: GE HealthCare is building vertically — scanner hardware, AI reconstruction, workflow software, clinical network connections. Every layer added makes the platform stickier and raises the switching cost for health systems. Intelerad’s cloud-native enterprise architecture was the missing piece that connected the imaging workflow to the enterprise IT layer. That’s not a product; that’s a platform moat.
Acquisition Closed
Imaging Software
Cloud Platform
Market Movers
| Ticker | Company | Price | Wk Change |
|---|
| ISRG ★ | Intuitive Surgical | $511.40 | ▲ 8.9% |
| SYK | Stryker | $344.80 | ▲ 0.4% |
| JNJ | Johnson & Johnson | $243.20 | ▲ 1.3% |
| STE | STERIS | $227.50 | ▲ 0.7% |
| BDX | BD (Becton Dickinson) | $157.80 | ▲ 0.5% |
| ABT | Abbott | $97.40 | ▲ 0.6% |
| MDT | Medtronic | $88.50 | ▲ 2.7% |
| EW | Edwards Lifesciences | $81.80 | ▲ 1.0% |
| GEHC | GE HealthCare | $75.30 | ▲ 0.9% |
| BSX | Boston Scientific | $65.20 | ▲ 1.5% |
★ Biggest Mover: ISRG surged 8.9% after beating Q1 2026 estimates with non-GAAP EPS of $2.50 and $2.77B in revenue, raising its 2026 da Vinci procedure growth outlook and improving gross margin guidance. MDT gained 2.7% on the week as two cardiovascular deals closed in 48 hours — the CathWorks acquisition completion and the Pulnovo Medical investment. Sorted by stock price, highest to lowest. Prices reflect approximate close, week of April 21–25, 2026. For illustrative purposes only.
Deep Dive
Wire-Free Is the Destination: Medtronic’s Two-Deal Week Points at One North Star
The headline numbers are different. The thesis is the same. Medtronic closed a $585 million acquisition of a coronary physiology AI platform in the same 48-hour window it led a $100 million investment in a pulmonary artery denervation company with a commercial agreement attached. Read these as isolated deals and they look like portfolio diversification. Read them together and they describe a single architectural bet: the wire-guided catheterization lab has a replacement coming, and Medtronic intends to build it.
In coronary physiology, the traditional FFR measurement requires threading a pressure wire through the coronary artery, administering adenosine to induce hyperemia, and taking measurements at a single transducer location. CathWorks’ FFRangio replaces that workflow with AI computation applied to the routine angiogram already being acquired — no additional wire, no drug administration, no single-point limitation. Diagnostic accuracy data published in JACC shows 93% accuracy against wire-based FFR. The clinical value is not marginal; it is categorical.
In pulmonary hypertension, the standard treatment approach relies on vasodilators, endothelin receptor antagonists, and prostacyclin analogs — therapies that manage the disease but do not interrupt its progression. Pulnovo’s PADN technology addresses a different mechanism: the sympathetic nerve network surrounding the pulmonary artery that drives the vasoconstriction and vascular remodeling underlying PH. Radiofrequency ablation of that nerve network reduces pulmonary artery pressure directly, without requiring lifetime medication. The PADN catheter is already commercially available in China and carries FDA Breakthrough Device designation for three PH subtypes — a regulatory head start most companies entering the space do not have.
The strategic logic connecting these two deals to Medtronic’s existing renal denervation franchise is not subtle. Medtronic received FDA approval for the Symplicity Spyral renal denervation system in December 2023 and has since grown its cardiac ablation solutions revenue by 71% year-over-year, driven largely by pulsed field ablation. The company has demonstrated that it can scale catheter-based ablation and denervation technologies through its global cath lab relationships. CathWorks gives it the AI-guided diagnostic platform to identify who needs intervention. PADN gives it a new interventional therapy for a disease with no good ones. (Sources: Med-Tech Insights; MassDevice)
The pattern is now visible across three disease areas: coronary artery disease (FFRangio), hypertension (Symplicity Spyral RDN), pulmonary hypertension (Pulnovo PADN). In each, Medtronic is using AI computation or catheter-based denervation to replace a more invasive standard-of-care workflow. That is not three bets — that is one coherent strategy applied to three markets. The question for competitors is which market Medtronic moves into next with the same playbook.
The Builder’s Take
Medtronic Bought Expensive Software Twice. Was It Worth It?
$585 million for coronary AI and $100 million for a pulmonary denervation commercial option, both in 48 hours. Medtronic CFO Thierry Piéton said in January the company would “step up” M&A in 2026. That was not a figure of speech. If the wire-free thesis is right — that AI computation replaces pressure wires and ablation replaces chronic medication — both deals were priced at the early innings. If the AI proves less reliable than the wires it replaces, or if PADN clinical trials disappoint in FDA-qualifying studies, Medtronic bought expensive optionality twice. The 2.7% weekly stock gain suggests the market is leaning toward the thesis being right. Surgical CFOs should be watching these outcomes closely before they write their own commercial roadmaps.
Fun Fact
💡 Fun Fact — The Cath Lab Number That Should Surprise You
Despite strong clinical evidence that fractional flow reserve guidance reduces unnecessary coronary interventions by up to 37%, wire-based FFR is used in fewer than 10% of coronary procedures globally. The leading reason: procedure time, cost, and the need for adenosine infusion. CathWorks’ FFRangio derives the same measurement from images already being acquired — no additional steps. The adoption ceiling on coronary physiology guidance is not clinical skepticism; it is workflow friction.
Trivia
MedTech Trivia
Fractional flow reserve was first described as a clinical concept in the early 1990s. The landmark DEFER trial, which validated using FFR to defer percutaneous coronary intervention in non-ischemic lesions, was published in a major cardiology journal in 2001. What was the five-year finding from the DEFER trial that made FFR-guided decision-making the gold standard for coronary physiology assessment?
👇 Scroll to the footer for the answer
MedTech Word Search
🧩 Find the Hidden MedTech Terms — Click to Highlight
CATHWORKS
MEDTRONIC
CORONARY
ACUITYMD
FFRANGIO
PULNOVO
DENERVATION
ANGIOGRAM
Words hidden in all 8 directions (→↓↘↗ and reverses). Click any letter in a word to reveal the full word.
Quick Question
Medtronic now has two denervation plays — renal (Symplicity Spyral) and pulmonary (Pulnovo PADN) — plus an AI-guided coronary physiology platform (CathWorks FFRangio). Which of these three bets has the best risk-adjusted return, and why? Hit reply — I read every response.
Sponsor
